

Dr. Ayman Hussien Shaamash

MBBCH, MSc., MD. (Egypt) Professor of OB./Gyn. Faculty of Medicine. King khalid University





Contents:

- **Congenital Anomalies**




- The Complete formation and differentiation of the müllerian ducts depend on completion of 3 phases of development as follows:
- Organogenesis: One or both müllerian ducts may not develop fully, resulting in uterine agenesis or hypoplasia (bilateral) or unicornuate uterus
- Fusion: [lateral fusion] the lower segments of the paired müllerian ducts fuse to form the uterus, cervix, and upper vagina. Failure of fusion results in anomalies such as bicornuate or didelphys uterus.
 - [Vertical fusion]: fusion of the ascending sinovaginal bulb with the descending müllerian system forms a normal patent vagina, while incomplete vertical fusion results in an imperforate hymen or septum.
- <u>Septal resorption:</u> After fusion, a central septum is present, is resorbed to form a single uterine cavity and cervix. Failure of resorption is the cause of septate uterus





- Müllerian duct anomalies are estimated to occur in 0.5-3% of women.
- The true prevalence is unknown because the anomalies usually are discovered in patients presenting with infertility.
- Full-term pregnancies have occurred in patients with forms of bicornuate, septate, or didelphys uteri; therefore, true prevalence may be slightly higher than currently estimated.






Morbidity of Mullerian Anomalies


- Patients with müllerian duct anomalies have a higher incidence of infertility, repeated first-trimester spontaneous abortions, fetal intrauterine growth retardation, fetal malposition, preterm labor, and retained placenta
- Certain types of the anomaly can increase morbidity, such as in patients with obstructed or partially obstructed müllerian systems who present with hematosalpinx, hematocolpos, retrograde menses, and endometriosis
- In addition, a fairly high association exists between müllerian duct anomalies and renal anomalies such as unilateral agenesis



Diagnosis of Mullerian Anomalies

- History
- Clinical Examination
- Investigation:
- 1- HSG
- 2-3 D U/S
- 2- Laparoscopy
- 4-Hysteroscopy
- 5- MRI







Bicornuate VS Spetate


- The role of reconstructive surgery is difficult to assess esp in infertility
- Consideration should be confined to women with recurrent pregnancy loss
- * cerclage
- *Hysteroscopic resection of the septum
- *? Metroplasty

11



II- Endometrial Polypi


- Is the most common endometrial benign tumor at any age especially at premenopausal time
- Presentation:
- Irregular bleeding
- Menorrhagia
- Protrusion through the cervix






III- Adenomyosis

- Invasion of endometrial glands and stroma into myometrium
- Adenomyosis is thought to affect 1% of women and is typically diagnosed in the 4th and 5th decades of life
- The aetiology is unclear, and until recently a diagnosis was made only after invasive and Hysterectomy







III- LEIOMYOMATA (FIBROIDS)

Epidemiology

- Diagnosed in approximately 40-50% of reproductive age women >35 years
- More common, larger, and occur at earlier age in black women
- Most common indication for major surgery in females
- Minimal malignant potential (1:1000)
- Tend to regress after menopause

17



<u>Pathogenesis</u>

arise from smooth muscle (Estrogen stimulates monoclonal- proliferation starts from a single cell) and Progesterone inhibits apoptosisis most responsible for fibroid growth.

Degenerative changes (if tumour outgrows blood supply)

- 1. Hyaline degeneration (most common degenerative change)
- 2. Cystic degeneration (from breakdown of hyaline)
- 3. Red degeneration (hemorrhage into tumour, may occur with pregnancy)
- 4. Fatty degeneration
- 5. Calcification
- 6. Sarcomatous degeneration (extremely rare)
- parasitic myoma tumour becomes attached to omentum or small bowel mesentery, develops new blood supply, and loses connection to uterus




Clinical Features

- Majority asymptomatic (60%), often discovered on TVS
- 1- abnormal uterine bleeding (30%)

Dysmenorrhea, menorrhagia

- 2- Pressure/bulk symptoms (20-50%)
- pelvic pressure/heaviness
- increased abdominal girth
- urinary frequency and urgency
- acute urinary retention (rare but surgical emergency!)
- constipation, bloating (rare)
- 3- Acute pelvic pain if:
- fibroid degeneration
- fibroid torsion (subserosal pedunculated)
- 4- <u>infertility</u> (submucosal)
- 5-Pregnancy complications and difficult C-section







- 1. Pelvic / abdominal exam
- 2. Ultrasound / saline sonohysterography
- 3. Laparoscopy
- 4. MRI / CT scan
- 5. Rule out endometrial pathology

Pelvic / abdominal exam


Victoria de la complexión de la







MRI of Uterine Fibroid





Treatment of fibroids

- Only if symptomatic, rapidly enlarging, or menorrhagia (treat anemia if present)
- I- Conservative approach (watch and wait) if
- symptoms absent or minimal
- fibroids <6-8 em or stable in size
- not submucosal (submucosal fibroids are more likely to be symptomatic)
- virtually all postmenopausal patients fall into this category (no increase in size or bleeding)



Treatment of fibroids cont.

11-Medical approach

- Antiprostaglandins (ibuprofen)
- Tranexamic acid (Cyklokapron®)
- OCP/Depo-Provera®
- GnRH agonist leuprolide (Lupron@), or
- Androgen derivative danazol (Danocrine®). Short-term use only (6 months). <u>Often used pre-myomectomy to</u> <u>facilitate surgery (reduces fibroid size)</u>
- Selective progesterone receptor modulators -- currently in clinical trials. Prototype is RU486 which reduces fibroid volume by 50% after 3 months without side effects of GnRH agonists


21





Treatment of fibroids cont.


III - Interventional radiology approach

- uterine artery embolization occludes both uterine arteries. Shrinks fibroids by 50% at 6 months.
- Improves menorrhagia in 70- 90% within 1-2 months (not an option in women considering childbearing)











Advantages of UFE

- Minimally invasive, complications rare
- Treats all fibroids simultaneously
- low recurrence rate
- Short recovery period
- No blood loss
- Avoids general anesthesia
- Preserves uterus

2



Limitations & Complications

- 1. ONLY for interstitial myoma
- 2. NOT for very huge myoma
- 3. NOT for women desire fertility
- 4. NOT if malignancy is suspected
- 5. Very rarely uterine necrosis
- 6. Very rarely ovarian failure




Myomectomy

IV- Surgical approach

- Myomectomy (hysteroscopic, transabdominal or laparoscopic approach) preserves childbearing capabilities
- Hysterectomy (abdominal or vaginal, depending on fibroid size)
- Avoid operating on fibroids during pregnancy (due to +++ vascularity);

expectant management only





IV-Endometriosis

Etiology

- Not fully understood
- Proposed mechanisms (combination likely involved)
- 1. Retrograde menstruation theory of Sampson
- transtubal regurgitation during menstruation
- endometrial cells most often found in dependent sites of the pelvis
- 2. <u>immunologic theory</u> altered immunity may limit clearance of transplanted endometrial cells from pelvic cavity (~ NK cell activity?)
- 3. Metaplasia of coelomic epithelium
- undefined endogenous biochemical factor may induce undifferentiated peritoneal cells to develop into endometrial tissue
- 4. <u>Lymphatic flow</u> from uterus to ovary may lead to ovarian endometriosis
- 5. Extrapelvic disease: due to vascular or lymphatic dissemination of cells



Endometriosis cont.

Epidemiology

- Incidence: 15-30% of premenopausal women
- Mean age at presentation: 25-30 years
- Regresses after menopause

Risk Factors

- Family history (7-10 fold increased risk if affected 1st degree relative)
- Obstructive anomalies of the genital tract (earlier onset)
- Nulliparity
- Age >25 years



Endometriosis cont.

Frequency


- Endometriosis occurs in 7-10% of women in the general population
- Endometriosis has a prevalence rate of 20-50% in infertile women
- And as high as 80% in women with chronic pelvic pain
- Evidence of endometriosis was found during laparoscopy in 20-50% of asymptomatic women




Endometriosis cont.

Sites of Occurrence

- Ovaries 60% patients have ovarian involvement
- Broad ligament
- Peritoneal surface of the cul-de-sac (uterosacral ligaments)
- Rectosigmoid colon
- Appendix







Clinical Features

- My be asymptomatic
- Cyclic symptoms due to swelling and bleeding of ectopic endometrium,
- secondary dysmenorrhea
- deep dyspareunia
- sacral backache with menses
- pain may become constant but remains worse perimenstrually
- Premenstrual and postrnenstrual spotting
- Infertility
- 30-40% of patients with endometriosis will be infertile
- 15-30% of those who are infertile will have endometriosis
- Bowel and bladder symptoms
- Frequency, dysuna, hematuria
- Diarrhea, constipation, hematochezia, dyschezia
- Tender nodularity of uterine ligaments and cul-de-sac
- Fixed retroversion of uterus
- Firm, fixed adnexal mass (endometrioma)



Endometriosis cont.

<u>Investigations</u>: definitive diagnosis requires

- direct visualization of lesions typical at laparoscopy
- biopsy and histologic exam of specimens
- LAPAROSCOPY
- dark blue or brownish-black implants on the uterosacral ligaments, cul-de-sac, or anywhere in the pelvis
- endometrioma: chocolate cysts in the ovaries
- "powder-bum" lesions on the peritoneal surface
- early white lesions and blebs
- •CA-125
- may be used as marker of response to medical therapy



Grading of Endometriosis

(American Society of Reproductive Medicine)

- It Takes into account:
- 1- Location: peritoneal, ovarian and DP
- 2-Size: <1 cm,1-3 cm and > 3cm
- 3-Infilteration:Superficial and Deep
- 4-Adhesion:filmy or dense- extent :
- (< 1/3,2/3 or >2/3 of pelvis)

45



Laparoscopic Staging:

Stage I: Minimal (1-5 points)

Stage II: Mild (6-15 points)

Stage III: Moderate (16-40 points)

Stage IV: Severe (> 40 points)



Endometriosis cont.

Treatment

 depends on the severity of symptoms, extent of disease, desire for future fertility, and threat to GI/GU systems

Medical

- 1- NSAIDs (e.g, naproxen sodium)
- 2-pseudopregnancy
- cyclic/continuous estrogen-progestin (OCP)
- medroxyprogesterone (Depo-Provera®)
- 3- pseudomenopause [2nd line: only short-term «6 months) due to osteoporotic potential with prolonged use]
- • danazol (Danocrine®) side effects:weight gain,fluid retention, acne, hirsutism,voice change
- • GnRH agonist (suppresses pituitary GnRH leuprolide (Lupron®) =)
- side effects: hot flashes, vaginal dryness, reduced libido
- can use up to 12 months with add-back progestin or estrogen



Endometriosis cont.

Surgical

- Laparoscopy using laser, electrocautery ablation/resection of implants, lysis of adhesions, ovarian cystectomy of endometriomas
- ± laparotomy for cytoreduction of pelvic endometriosis
- ± follow-up with medical treatment for pain control NOT fertility
- Radical surgery

This involves total hysterectomy with bilateral oophorectomy and cytoreduction of visible endometriosis

